Should older adults with AML receive post-remission therapy?

被引：3
|
作者：
Stone, Richard M. [1 ]
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA
来源：
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2015年 / 28卷 / 2-3期
关键词：
AML; Chemotherapy; Post-remission; ACUTE MYELOID-LEUKEMIA; 1ST COMPLETE REMISSION; LOW-DOSE CYTARABINE; ACUTE NONLYMPHOCYTIC LEUKEMIA; RANDOMIZED PHASE-III; INDUCTION CHEMOTHERAPY; MYELODYSPLASTIC SYNDROME; EUROPEAN ORGANIZATION; CELL TRANSPLANTATION; ELDERLY-PATIENTS;
D O I：
10.1016/j.beha.2015.10.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The evolution of post-remission therapy in older adults has for the most part mirrored that for younger adults. However, the suitability of those regimens for an older population is less clear-cut, mainly due to poorer tolerance of therapy and a relatively higher level of disease resistance. Not only is intensive post-remission therapy not appropriate for the majority of older adults, but the role of intensive induction therapy is also unclear. Treatment goals in patients over 55-65 years differ from those in younger patients and may not necessarily be curative but life-prolonging or purely palliative. This paper reviews treatments for older AML patients in an effort to shed some light on choosing appropriate therapy. (C) 2015 Published by Elsevier Ltd.
引用
收藏
页码：106 / 111
页数：6
相关论文
共 50 条
  • [21] Time to Count Recovery after Post-Remission Chemotherapy in AML Patients
    Paras, Gabrielle
    Othus, Megan
    Shaw, Carole M.
    Russell, Katie
    Halpern, Anna B.
    Appelbaum, Jacob S.
    Hendrie, Paul C.
    Walter, Roland B.
    Percival, Mary-Elizabeth M.
    [J]. BLOOD, 2022, 140 : 6080 - 6081
  • [22] Retrospective analysis of post-remission modalities in AML patients with normal karyotype
    Chae, Yee Soo
    Sohn, Sang Kyun
    Kim, Jong Gwang
    Cho, Yoon Young
    Moon, Joon Ho
    Ahn, Byung Min
    Kim, Shi Nae
    [J]. BLOOD, 2007, 110 (11) : 132B - 132B
  • [23] Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia
    Advani, Anjali S.
    Jin, Tao
    Ramsingh, Giridharan
    Tiu, Ramon
    Saber, Wael
    Theil, Karl
    Sobecks, Ronald
    Sekeres, Mikkael
    Copelan, Ed
    Sungren, Shawnda
    Tripp, Barbara
    Kalaycio, Matt
    [J]. LEUKEMIA & LYMPHOMA, 2008, 49 (08) : 1560 - 1566
  • [24] AML: final remission status prior to post-remission therapy overrides negative prognostic impact of early blast persistence during induction therapy
    Ihlow, J.
    Gross, S.
    Busack, L.
    Herneth, A.
    Blau, I. -W.
    Anagnostopoulos, I.
    Floercken, A.
    Bullinger, L.
    Westermann, J.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 308 - 308
  • [25] Impact of post-remission therapy on survival of older patients with AML treated with intensive chemotherapy: Results of the multicenter ALFA-9803 trial.
    Turlure, Pascal
    Gardin, Claude
    Malfuson, Jean-Valere
    Thomas, Xavier
    Terre, Christine
    Contentin, Nathalie
    Raffoux, Emmanuel
    de Botton, Stephane
    Pautas, Cecile
    Reman, Oumedaly
    Bourhis, Jean-Henri
    Dhedin, Nathalie
    Janvier, Maud
    Fenaux, Pierre
    Castaigne, Sylvie
    Michallet, Mauricette
    Preudhomme, Claude
    de Revel, Thierry
    Bordessoule, Dominique
    Dombret, Herve
    [J]. BLOOD, 2006, 108 (11) : 128A - 129A
  • [26] BIOMARKER BASED POST-REMISSION STRATEGY IMPROVES THE OUTCOME OF ADULT AML PATIENTS
    Di Veroli, A.
    Buccisano, F.
    Maurillo, L.
    Piciocchi, A.
    Picardi, A.
    Cerretti, R.
    Del Principe, M. I.
    De Bellis, E.
    De Angelis, G.
    Cudillo, L.
    Cicconi, L.
    Rossi, V.
    Voso, M. T.
    Lo Coco, F.
    Amadori, S.
    Arcese, W.
    Venditti, A.
    [J]. HAEMATOLOGICA, 2017, 102 : 70 - 70
  • [27] Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia
    Walter, Roland B.
    Medeiros, Bruno C.
    Powell, Bayard L.
    Schiffer, Charles A.
    Appelbaum, Frederick R.
    Estey, Elihu H.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (05): : 739 - 742
  • [28] Myeloablative therapy and autologous (ABMT) or allogeneic marrow transplantation (BMT) are equivalent post-remission therapy in acute myelogenous leukaemia (AML).
    Novitzky, N
    Thomas, V
    [J]. BLOOD, 1995, 86 (10) : 386 - 386
  • [29] Race and intensity of post-remission therapy in acute myeloid leukemia
    Brady, Anna K.
    Fu, Alex Z.
    Earl, Marc
    Kalaycio, Matt
    Advani, Anjali
    Saunthararajah, Yogen
    Sobecks, Ronald
    Copelan, Edward
    Sekeres, Mikkael A.
    [J]. LEUKEMIA RESEARCH, 2011, 35 (03) : 346 - 350
  • [30] The role of post-remission chemotherapy for older patients with acute myelogenous leukemia
    Abou-Jawde, RM
    Sobecks, R
    Pohlman, B
    Rybicki, L
    Advani, A
    Sekeres, M
    Kalaycio, M
    [J]. LEUKEMIA & LYMPHOMA, 2006, 47 (04) : 689 - 695
12345